PA-SYNERGIS-SOFTWARE
9.3.2022 15:24:09 CET | Business Wire | Press release
Synergis Software, a global leader in engineering document management and workflow solutions, today announced a rebrand and new website in synchrony with major investments in product development and customer success. These initiatives will fast track the company’s delivery of superior products and services to their global customer base.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220309005289/en/
“We see so much opportunity to have a positive impact on the customers we serve, which is why we’re making major investments in the company," states Scott Lamond, vice president of marketing at Synergis Software. "We want our brand to align with our mission of transforming the way our customers work— providing greater clarity, control, alignment, and harmony—so they can accelerate engineering projects, streamline operations, reduce risk, and lower costs." Watch the rebrand video .
The Adept platform is used by 120,000 users worldwide, including Dow Chemical, Con Edison, Amazon, Merck, and General Mills, and is managing over $1B in digital assets.
“Adept manages billions of dollars of digital assets containing priceless Dow intellectual property, with thousands of users across several dozen global sites," says Teresa Yang, Product Manager, Document Management, Dow Chemical.
Synergis is committed to accelerating the company’s growth and elevating the value delivered to customers with significant investments in their products.
“We’re tripling the size of our software development organization. By the end of 2022, our team will have grown by 218% in just two years,” explains Todd Cummings, vice president of research and development at Synergis. “The added positions include developers, QA staff, product managers, DevOps, SCRUM Masters, and User Experience professionals. Key leaderships roles are in place to help us refine the processes, tools, and methods we use to develop and deliver more value, faster.”
Synergis is investing substantially in the Adept platform, including the upcoming release of a new, integrated visualization solution for 2D and 3D engineering designs and other document types, along with major new feature enhancements and support for new versions of mainstream CAD systems. A new Cloud version of Adept is underway for customers who want to lower their IT costs and simplify deployment and upgrades.
“We’ll continue to build on Synergis Software’s legacy of extraordinary, love-based service and treating customers like family," adds Lamond. Toward that end, Synergis is expanding its customer success team, developing an online “Adept Academy”, and launching three new services options, including:
- Ongoing Technical Consulting - Customers can work one-on-one with a dedicated Adept technical consultant on a regular basis to improve their Adept environment, streamline processes, remove roadblocks, and increase the value of Adept to their organization. Synergis experts will provide strategic and technical guidance on nearly any type of project to help customers reach their goals.
- Remote Adept Administration - Customers can outsource the day-to-day application management and administration of Adept to our experienced technical staff to keep their resources focused on what’s most important to their business. Our managed services will help keep our customer’s Adept environment optimized and lower operating costs.
- Adept Server Hosting - Customers can outsource the hosting of their entire Adept Server environment to free up IT resources, lower operating costs, and improve security.
Synergis Software’s focus and investments in service and support will help maintain their strong leadership position in the market, as validated in the rankings on the G2 software review site.
“We couldn’t have arrived at this moment without 30 years of thoughtful, collaborative, and visionary support from our customer community and the individuals who have shaped us,” added Lamond. “We’re grateful for their influence as we build our future together.”
About Synergis Software
Synergis Software is a global leader in document management and workflow solutions and is the creator of Synergis Adept software. Adept serves more than 120,000 users across dozens of industries providing fast, centralized access to design and business documents in a secure, collaborative environment. Adept Integrator connects enterprise applications so critical data and business processes can flow seamlessly across the entire IT infrastructure.
Named the customer service leader in the global engineering information management market by Frost & Sullivan and ranked in the Top 5 globally by Helpdesk International for three consecutive years, the company's commitment to its customers is unwavering.
Founded in 1985, Synergis Technologies, LLC is headquartered in Bucks County, PA and is privately owned and funded. For more information, visit SynergisSoftware.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220309005289/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces filing of registration statement for proposed initial public offering8.6.2026 13:20:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, announces today that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares. The timing of the offering, number of shares to be offered, and the price range for the proposed offering have not yet been determined. Bending Spoons has applied to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol “BSP.” Goldman Sachs International, J.P. Morgan, and Allen & Company LLC are acting as joint lead book-running managers for the proposed offering. Wells Fargo Securities, BofA Securities, Jefferies, Evercore ISI, BNP Paribas, Mizuho, Societe Generale, Crédit Agricole CIB, IMI – Intesa Sanpaolo, UniCredit, and Banca Akros – Gruppo Banco BPM are acting as joint book-running managers for the proposed offering. The proposed offering is subject to market and other condit
Xsolla to Attend SuperReturn International 2026 to Advance Strategic Partnerships and Expand Its Presence in Global Private Capital8.6.2026 13:15:00 CEST | Press release
Xsolla Heads to Berlin to Advance and Foster Private Capital Relationships, Advance and Engage Senior Investors Across the Private Capital Ecosystem Xsolla, a global leader in video game commerce, today announced its participation in SuperReturn International 2026, taking place June 8–12 at the InterContinental Berlin. Uniting more than 6,000 senior attendees, including 2,000+ LPs and 3,000 GPs, SuperReturn International is widely recognized as the capital of private capital with the best investment opportunities globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260607269536/en/ Graphic: Xsolla The video game industry has matured into one of the largest and most resilient segments of the global entertainment economy, outpacing film and music combined, driving continuous growth through shifting market cycles. Yet the infrastructure powering how games are sold, monetized, and distributed worldwide remains under-examined
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom